140 related articles for article (PubMed ID: 15968197)
1. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
3. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
[TBL] [Abstract][Full Text] [Related]
4. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
5. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas.
Mishra SK; Crasta JA
Int J Gynecol Cancer; 2010 May; 20(4):537-41. PubMed ID: 20442586
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
[No Abstract] [Full Text] [Related]
14. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
16. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; Nupponen NN; Butzow R
Br J Cancer; 2004 Dec; 91(12):2048-55. PubMed ID: 15583695
[TBL] [Abstract][Full Text] [Related]
18. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
